| Date Filed | Type | Description |
| 08/21/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/15/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/05/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ...|
Docs:
|
"CERTIFICATE OF DESIGNATION OF SERIES BB CONVERTIBLE PREFERRED STOCK OF PRESSURE BIOSCIENCES, INC. 1. Series BB Preferred Stock Designation and Rank . Designation. The designation of such series of the Preferred Stock shall be the Series BB Convertible Preferred Stock, par value $0.01 per share . The maximum number of shares of Series BB Preferred Stock shall be One Thousand shares. Rank. The Series BB Preferred Stock shall rank prior to the common stock, par value $0.01 per share of Pressure BioSciences, Inc. , and subordinate to the Series AA and Series CC Preferred Stock, and to all other classes and series of equity securities of the Company which by its terms does not rank on a parity with or senior to the Series BB Preferred Stock . The Series BB Preferred Stock shall be subordinate t...",
"CERTIFICATE OF DESIGNATION OF SERIES CC CONVERTIBLE PREFERRED STOCK OF PRESSURE BIOSCIENCES, INC. 1. Series CC Preferred Stock Designation and Rank . Designation. The designation of such series of the Preferred Stock shall be the Series CC Convertible Preferred Stock, par value $0.01 per share . The maximum number of shares of Series CC Preferred Stock shall be Two Thousand shares. Rank. The Series CC Preferred Stock shall rank prior to the common stock, par value $0.01 per share , shall rank pari passu to the Series AA Preferred Stock, and shall rank prior to all other classes and series of equity securities of the Company which by its terms does not rank on a parity with or senior to the Series CC Preferred Stock . The Series CC Preferred Stock shall be subordinate to and rank junior to ..." |
|
| 04/03/2023 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 03/06/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities Interactive Data |
| 01/05/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 12/06/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 11/21/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/15/2022 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 05/18/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/17/2022 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 04/05/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 04/01/2022 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 01/04/2022 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 11/19/2021 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 11/16/2021 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 08/20/2021 |
8-K
| Quarterly results |
| 08/18/2021 |
10-Q
| Quarterly Report for the period ended June 30, 2021 |
| 08/17/2021 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 07/30/2021 |
SC 13G/A
| EAGLE EQUITIES LLC reports a 12% stake in Pressure BioSciences, Inc. |
| 07/16/2021 |
SC 13G
| EAGLE EQUITIES LLC reports a 5.2% stake in Pressure BioSciences, Inc. |
| 05/17/2021 |
10-Q
| Quarterly Report for the period ended March 31, 2021 |
| 04/15/2021 |
10-K
| Annual Report for the period ended December 31, 2020 |
| 04/01/2021 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 03/15/2021 |
SC 13G
| LG CAPITAL FUNDING, LLC reports a 9.9% stake in Pressure BioSciences, Inc. |
| 12/31/2020 |
8-K
| Quarterly results |
| 12/09/2020 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 11/16/2020 |
10-Q
| Quarterly Report for the period ended September 30, 2020 |
| 11/06/2020 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 10/30/2020 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 10/09/2020 |
8-K
| Quarterly results |
| 08/14/2020 |
10-Q
| Quarterly Report for the period ended June 30, 2020 |
|